1
|
Hansen T, Weckesser M, Schäfers M, Gunnemann A. [Uncommon manifestation of prostate cancer : Sister Mary Joseph's nodule]. Urologe A 2016; 56:50-53. [PMID: 27272004 DOI: 10.1007/s00120-016-0130-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We report on the case of an 81-year-old man suffering from prostate cancer for several years. In recent months, PSA levels increased, and 68Ga-PSMA-PET-CT (PSMA: prostate-specific membrane antigen) imaging demonstrated suspicious lesions in the paravesical area and an umbilical tumor mass. Local excision was performed. Histologically, the tumor mass was diagnosed as metastasis of the prostate cancer, which is also designated as Sister Mary Joseph's nodule. Umbilical metastases of primary prostate cancer are extremely rare; however, they are of clinical importance since they are commonly associated with tumor progress and with a particularly poor prognosis.
Collapse
Affiliation(s)
- T Hansen
- Institut für Pathologie, Klinikum Lippe GmbH, Röntgenstraße 18, 32756, Detmold, Deutschland.
| | - M Weckesser
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - M Schäfers
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - A Gunnemann
- Klinik für Urologie, Klinikum Lippe GmbH, 32756, Detmold, Deutschland
| |
Collapse
|
2
|
Pfob CH, Ziegler S, Graner FP, Köhner M, Schachoff S, Blechert B, Wester HJ, Scheidhauer K, Schwaiger M, Maurer T, Eiber M. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43:1962-70. [PMID: 27207281 DOI: 10.1007/s00259-016-3424-3] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Accepted: 05/11/2016] [Indexed: 12/18/2022]
Abstract
PURPOSE Positron emission tomography (PET) agents targeting the prostate-specific membrane antigen (PSMA) are currently under broad clinical and scientific investigation. (68)Ga-PSMA HBED-CC constitutes the first (68)Ga-labelled PSMA-inhibitor and has evolved as a promising agent for imaging PSMA expression in vivo. The aim of this study was to evaluate the whole-body distribution and radiation dosimetry of this new probe. METHODS Five patients with a history or high suspicion of prostate cancer were injected intravenously with a mean of 139.8 ± 13.7 MBq of (68)Ga-PSMA HBED-CC (range 120-158 MBq). Four static skull to mid-thigh scans using a whole-body fully integrated PET/MR-system were performed 10 min, 60 min, 130 min, and 175 min after the tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses (ED) were calculated using OLINDA/EXM. RESULTS Injection of a standard activity of 150 MBq (68)Ga-PSMA HBED-CC resulted in a median effective dose of 2.37 mSv (Range 1.08E-02 - 2.46E-02 mSv/MBq). The urinary bladder wall (median absorbed dose 1.64E-01 mGv/MBq; range 8.76E-02 - 2.91E-01 mGv/MBq) was the critical organ, followed by the kidneys (median absorbed dose 1.21E-01 mGv/MBq; range 7.16E-02 - 1.75E-01), spleen (median absorbed dose 4.13E-02 mGv/MBq; range 1.57E-02 - 7.32E-02 mGv/MBq) and liver (median absorbed dose 2.07E-02 mGv/MBq; range 1.80E-02 - 2.57E-02 mGv/MBq). No drug-related pharmacological effects occurred. CONCLUSION The use of (68)Ga-PSMA HBED-CC results in a relatively low radiation exposure, delivering organ doses that are comparable to those of other (68)Ga-labelled PSMA-inhibitors used for PET-imaging. Total effective dose is lower than for other PET-agents used for prostate cancer imaging (e.g. (11)C- and (18)F-Choline).
Collapse
Affiliation(s)
- Christian H Pfob
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany.
| | - Sibylle Ziegler
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| | - Frank Philipp Graner
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| | - Markus Köhner
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| | - Sylvia Schachoff
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| | - Birgit Blechert
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| | - Hans-Jürgen Wester
- Chair of Pharmaceutical Radiochemistry, Department Chemie, Technische Universität München, Walther-Meissner-Str. 3, 85748, Garching, Germany
| | - Klemens Scheidhauer
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| | - Markus Schwaiger
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| | - Tobias Maurer
- Department of Urology, Technische Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany
| | - Matthias Eiber
- Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar; Ismaningerstrasse 22, 81675, Munich, Germany
| |
Collapse
|